Strategies to extend plasma half-lives of recombinant antibodies
- PMID: 19489651
- DOI: 10.2165/00063030-200923020-00003
Strategies to extend plasma half-lives of recombinant antibodies
Abstract
Recombinant antibodies, including whole antibodies, antibody fragments, antibody fusion proteins or conjugates, and more recently also small antibody mimetics, have found increasing applications as therapeutics, e.g. for the treatment of cancer or inflammatory diseases. While whole antibodies have an exceptionally long half-life, small antibody derivatives often suffer from rapid elimination from the circulation. In order to improve administration and therapeutic efficacy, modifications to extend the plasma half-life have been developed and implemented in these antibody formats. This review provides a comprehensive summary of the various strategies currently available to extend plasma half-lives of recombinant antibodies.
Similar articles
-
Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18. J Immunol. 2010. PMID: 20083659
-
Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review.Int J Biol Macromol. 2018 Nov;119:306-311. doi: 10.1016/j.ijbiomac.2018.07.141. Epub 2018 Jul 21. Int J Biol Macromol. 2018. PMID: 30041038 Review.
-
SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.Protein Eng Des Sel. 2010 Apr;23(4):195-202. doi: 10.1093/protein/gzp094. Epub 2010 Feb 4. Protein Eng Des Sel. 2010. PMID: 20299542
-
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9. J Drug Target. 2014. PMID: 24404896 Review.
-
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.Methods. 2014 Jan 1;65(1):114-26. doi: 10.1016/j.ymeth.2013.06.035. Epub 2013 Jul 17. Methods. 2014. PMID: 23872058
Cited by
-
The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.J Pers Med. 2025 Jan 28;15(2):51. doi: 10.3390/jpm15020051. J Pers Med. 2025. PMID: 39997328 Free PMC article. Review.
-
Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding.MAbs. 2016 Oct;8(7):1319-1335. doi: 10.1080/19420862.2016.1210747. Epub 2016 Aug 17. MAbs. 2016. PMID: 27532598 Free PMC article.
-
Dual targeting strategies with bispecific antibodies.MAbs. 2012 Mar-Apr;4(2):182-97. doi: 10.4161/mabs.4.2.19000. Epub 2012 Mar 1. MAbs. 2012. PMID: 22453100 Free PMC article. Review.
-
Advances in antibody-based therapy in oncology.Nat Cancer. 2023 Feb;4(2):165-180. doi: 10.1038/s43018-023-00516-z. Epub 2023 Feb 20. Nat Cancer. 2023. PMID: 36806801 Review.
-
Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria.Malar J. 2018 Nov 1;17(1):402. doi: 10.1186/s12936-018-2549-1. Malar J. 2018. PMID: 30384848 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources